Following the national trial, the future of -derived products in France raises many questions. Between commercial development, consumer expectations, and increased vigilance from public authorities, the issue can no longer be addressed solely from an economic perspective. It directly impacts traffic law, public health, and individual responsibility.
The central point is now well established: the legality of a derivative product for sale does not mean it is harmless while driving. In France, driving under the influence of drugs remains a criminal offense, even when the product consumed is a legally marketed derivative. This distinction between an authorized market and prohibited driving already shapes the present, and likely also the future, of the sector.
A derivatives market facing a clear limit
Cannabis- derived products have gained visibility in recent years, particularly with the widespread availability of hemp-based products offered within a regulated commercial framework. This development may have led some consumers to believe that a product that is legal to purchase is also neutral in all situations of use. However, this reasoning does not align with applicable traffic laws.
The key point of concern lies in distinguishing between the legality of the product itself and the potential illegality of driving after consumption. In practice, a legally sold derivative product can still expose the user to prosecution if it contains THC or if the substance consumed is classified as a narcotic. This separation of legal frameworks is essential for understanding the future of the sector.
Following the national trial, it is therefore likely that the market will continue to exist, but in an environment of heightened responsibility. Professionals will need to provide buyers with clearer information, while consumers will need to understand that a legal purchase is never a guarantee of fitness to drive.
The current legal framework in France: zero tolerance for driving
In France, driving under the influence of drugs remains a crime clearly punishable under the Highway Code. Article L.235-1 provides for up to three years' imprisonment and a €9,000 fine. When the offense is compounded by a blood alcohol level exceeding the legal limit, the penalties can be increased to five years' imprisonment and a €15,000 fine.
This framework is not merely theoretical. It is part of a sustainable road safety policy based on prevention, detection, and penalties. As of July 3, 2026, French authorities are maintaining a precautionary approach combined with enhanced enforcement, confirming that driving under the influence of drugs remains a priority for public action.
for the future of derivative products. Even if the commercial offering diversifies, the legal message remains simple: when it comes to driving, road safety protection takes precedence over the perceived legality of the purchased product.
The 2023 case law removed a major ambiguity
A significant step forward was taken with the French Court of Cassation's 2023 ruling. The highest court held that the sale of a product with a THC content below 0.30% does not exempt drivers from the offense of driving under the influence of drugs. In other words, the legality of the product on the market does not automatically protect the driver.
The Court adopted a particularly clear formula: the offense is established as soon as it is proven that a substance classified as a narcotic has been consumed, regardless of the quantity absorbed. This firm stance considerably weakens arguments based on low THC concentration or the product's legal origin.
For both users and distributors, this decision fundamentally changes the perception of risk. It requires moving beyond a purely commercial approach to one of compliance and caution. The future of derivatives will therefore also depend on better education about the potential consequences of misuse.
A strengthening of regulations confirmed in 2025
The regulatory framework was further strengthened in 2025. Article L.235-1 of the Highway Code was amended by the law of July 9, 2025, in a version which came into force on July 11, 2025. This legislative signal shows that the legislator has not chosen to relax, but on the contrary to consolidate the existing arsenal.
In the public debate, some imagined that a rise in the use of derivative products would lead to a more permissive adaptation of traffic laws. Recent developments show the opposite. French law continues to treat driving under the influence of drugs as a specific threat to public safety.
This trend will have lasting effects on the future of the sector. Manufacturers, retailers, and platforms will undoubtedly need to strengthen their information labels, warnings, and traceability practices. Business development will likely be inextricably linked to stricter transparency requirements.
The risks to your driving licence and the legal consequences
Repression is not limited to fines or imprisonment. Administrative and criminal sanctions related to driving under the influence of drugs also include measures directly affecting the driver's license. The Highway Code specifically provides for license suspension of up to 5 years.
In addition, drivers may be required to complete a road safety awareness course. These measures reflect a focus on driver responsibility, but also on protecting other road users. They serve as a reminder that, in matters of drugs, the consequences can be swift, tangible, and long-lasting.
In the context of derivatives, the risk is sometimes underestimated because the purchase takes place in a seemingly ordinary setting. However, the impact of a positive test can be particularly severe, even for a driver who thought they had consumed a product compatible with normal daily life. This discrepancy between perception and legal reality constitutes one of the major challenges for prevention.
Recent data that justifies the authorities' caution
Data from the French Monitoring Centre for Drugs and Drug Addiction (OFDT) confirms that the issue of road safety is far from marginal. In 2021, 46,660 drug tests conducted after accidents resulting in injury revealed a 6.5% positive rate. This level demonstrates that the presence of drugs in the context of accidents remains a measurable and concerning reality.
Cannabis remains the most widely used illegal drug in France. The official health bulletin of June 2025 indicates that approximately 900,000 daily users are affected. This level of consumption explains why road safety campaigns remain heavily focused on this issue, even when the discussion centers on derivative products rather than the traditional use of cannabis.
For policymakers, these figures justify maintaining a precautionary approach. The more widespread consumption becomes among the population, the greater the risk of normalization. And the more normalization progresses, the more important the need for a clear legal message becomes: a product can be legal to sell without being harmless from a driving perspective.
Impact on driving: a documented and high risk
The impact of cannabis on driving is well-documented and significant. According to the French Monitoring Centre for Drugs and Drug Addiction (OFDT), driving under the influence of cannabis greatly increases the risk of causing a fatal accident, by a much greater margin than several other risk factors. This finding is crucial, as it explains the continued strictness of the French regulations.
Beyond overall statistics, French accident analysis highlights the existence of driving errors linked to alcohol and/or cannabis in fatal accidents. The OFDT's SAM project focuses specifically on these risk mechanisms, allowing for a more in-depth analysis than simply observing positive results during tests.
In practical terms, the future of derivatives will also depend on what research continues to demonstrate about their effects in real-world situations. As long as impaired driving ability remains an established issue, the law will likely maintain a protective approach, even as the derivatives market continues to develop.
What future awaits derivative products after the national trial?
The future of derivative products in France thus seems to be heading towards a model of coexistence between limited commercial openness and absolute firmness in their conduct. This does not necessarily mean a market freeze, but rather a more mature framework in which consumer information becomes as important as the conformity of the product itself.
We can expect stricter labeling requirements, warning messages, and usage recommendations. Industry operators will have an interest in clearly stating that consuming a cannabis-derived product may impair driving, even when the product is legally offered for sale. This educational approach could become a market standard.
In the medium term, the sector's viability will undoubtedly depend on its ability to fully integrate road safety requirements. The development of derivative products can only thrive sustainably if it is accompanied by honest communication about the risks, clear dialogue with the authorities, and a shared understanding of the limits imposed by French law.
Ultimately, following the national trial, the debate no longer focuses solely on the possibility of selling derivative products, but on the conditions for their integration into the social and legal landscape. The French framework consistently reiterates that a legal product does not eliminate health risks, road safety risks, or driver liability.
The future of the sector will therefore depend on a demand for clarity. For consumers, the message must be unambiguous: if in doubt, do not drive after consuming alcohol. For professionals, the challenge is to build a credible market, compatible with road safety priorities and regulations that, to date, remain resolutely strict.
